{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:37:00Z","timestamp":1769096220837,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/iop.0b013e31828de0d6","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T09:30:18Z","timestamp":1364981418000},"page":"205-207","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of Preferences Between OnabotulinumtoxinA (Botox) and IncobotulinumtoxinA (Xeomin) in the Treatment of Benign Essential Blepharospasm"],"prefix":"10.1097","volume":"29","author":[{"given":"Rao V.","family":"Chundury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Holds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm.","volume":"113","author":"Roggenkamper","year":"2006","journal-title":"JNeural Transm"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/IOP.0b013e318244a380","article-title":"Gender differences in benign essential blepharospasm.","volume":"28","author":"Lee","year":"2012","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.iio.0000167238.26526.a8","article-title":"Benign essential blepharospasm.","volume":"45","author":"Ben Simon","year":"2005","journal-title":"IntOphthalmol Clin"},{"key":"R4-14-20210129","first-page":"453","article-title":"Essential blepharospasm.","volume":"54","author":"Henderson","year":"1956","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/01676830490506041","article-title":"Impact on quality of life of botulinum toxin treatments for essential blepharospasm.","volume":"23","author":"MacAndie","year":"2004","journal-title":"Orbit"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0404.2004.00357.x","article-title":"Health-related quality of life in blepharospasm or hemifacial spasm.","volume":"111","author":"Reimer","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00002341-199809000-00002","article-title":"Blepharospasm: past, present, and future.","volume":"14","author":"Anderson","year":"1998","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/112067210301300401","article-title":"Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.","volume":"13","author":"Calace","year":"2003","journal-title":"Eur J Ophthalmol"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/eye.2009.192","article-title":"Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.","volume":"24","author":"Cillino","year":"2010","journal-title":"Eye (Lond)"},{"key":"R10-14-20210129","first-page":"135","article-title":"Ophthalmologic use of botulinum A exotoxin.","volume":"20","author":"Carruthers","year":"1985","journal-title":"Can J Ophthalmol"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0161-6420(95)30757-9","article-title":"Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.","volume":"102","author":"Ainsworth","year":"1995","journal-title":"Ophthalmology"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002341-199012000-00005","article-title":"Botulinum A toxin injection. Failures in clinical practice and a biomechanical system for the study of toxin-induced paralysis.","volume":"6","author":"Holds","year":"1990","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00115-008-2486-2","article-title":"Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A.","volume":"79","author":"Vogt","year":"2008","journal-title":"Nervenarzt"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp.64.6.751","article-title":"Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.","volume":"64","author":"Jitpimolmard","year":"1998","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov Disord"},{"issue":"suppl 8","key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov Disord"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000064953","article-title":"Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy.","volume":"48","author":"Dressler","year":"2002","journal-title":"Eur Neurol"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasma randomized trial.","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov Disord"},{"issue":"suppl","key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2008.04.027","article-title":"Xeomin displays lower potency and is neutralized by anti-BOTOX antibodies.","volume":"51","author":"Meenakshi","year":"2008","journal-title":"Toxicon"},{"issue":"suppl 1","key":"R21-14-20210129","first-page":"S20","article-title":"Equivalent potency of Xeomin and Botox.","volume":"23","author":"Dressler","year":"2008","journal-title":"Mov Disorder"}],"container-title":["Ophthalmic Plastic & Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IOP.0b013e31828de0d6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:53:39Z","timestamp":1620957219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002341-201305000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0b013e31828de0d6","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}